Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs

详细信息    查看全文

• 作者：Toshio Ikeda ; Jun Sakurai ; Daisuke Nakayama ; Yoshihiro Takahashi ; Kiyoko Matsuo ; Yuko Shibuya ; Tomoko Gomi ; Hidekazu Moriya ; Shuzo Kobayashi
• 关键词：Pravastatin ; probucol ; crossover trial ; insulin resistance
• 刊名：American Journal of Hypertension
• 出版年：2004
• 出版时间：June 2004
• 年：2004
• 卷：17
• 期：6
• 页码：502-506
• 全文大小：80 K

文摘

Statins have been reported to have direct vascular effects independent of cholesterol reduction. To assess the antihypertensive effect of statins, a crossover study was designed to compare the depressor effect of pravastatin and probucol in hypertensive patients undergoing long-term treatment with antihypertensive drugs.

Methods

The subjects enrolled in this study were 52 hypertensive patients (22 men and 30 women, mean age 62.8 ± 9.3 years) who were treated with the same antihypertensive drugs for more than 1 year and had serum cholesterol levels of more than 5.69 mmol/L. In 26 subjects, pravastatin at a dose of 10 mg/d was given first for 6 months followed by treatment with probucol at a dose of 500 mg/d, and vice versa in the remaining 26 subjects. Serum lipids, apolipoproteins, glucose, and insulin were measured on the final day of the control period, and pravastatin and probucol treatments. The homeostatic model assessment insulin resistance index (HOMA-IR) was used to assess insulin resistance.

Results

The blood pressure decreased after pravastatin treatment (141.2 ± 4.7/81.3 ± 4.9 to 136.5 ± 5.3/80.6 ± 5.1 mm Hg, P < .001/.499), but did not decrease after probucol treatment (141.2 ± 4.7/81.3 ± 4.9 to 141.4 ± 4.9/80.8 ± 4.9 mm Hg, P = .832/.634). Total cholesterol decreased significantly after pravastatin (6.69 ± 0.69 to 5.23 ± 0.77 mmol/L, P < .001) and probucol treatment (6.69 ± 0.69 to 5.53 ± 0.64 mmol/L, P < .001). The HOMA-IR was decreased by probucol (1.92 ± 0.78 to 1.57 ± 0.59, P = .029), whereas pravastatin had no effect on HOMA-IR.

Conclusions

It can be concluded that the depressor effect of pravastatin may have an additional benefit in the treatment of hypertensive patients with hyperlipidemia without any adverse effect on insulin sensitivity.